An accomplished international operator, Mr. Lebbadi led the medical division for Johnson & Johnson and has successfully scaled several high-growth companies
VANCOUVER, BC, March 15, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has named Tarik Lebbadi as the Company’s new Chief Operating Officer, effective immediately. Mr. Lebbadi steps in to assume the role previously held by President & CEO Kelsey Ramsden. He is an accomplished international executive and operator with extensive experience in healthcare and technology, having served in a leadership position at Johnson & Johnson and at several high-growth technology companies. Most recently, he served in a strategic operational capacity at Aurora Cannabis through the industry’s legalization.
“I am thrilled to welcome Tarik to MINDCURE today,” said Kelsey Ramsden, President & CEO, MINDCURE. “With his diverse and relevant operational experience, he is the right leader to step in and drive our commercial team forward. His specific experience with Johnson & Johnson gives him an understanding of healthcare and the pace at which it operates, and he has significant hands-on experience with high-growth teams as well.”
Mr. Lebbadi began his career as a software engineer and has extensive operational experience with technology platforms. “Tarik’s specific software and technology experience will also be invaluable, both as an engineer and operator,” continued Mrs. Ramsden. “His experience with Johnson & Johnson aligns with MINDCURE’s strategy to be an integrated provider, from drug discovery through production and therapeutic support, with iSTRYM. His ability to drive strategy and execution across the board is a rare asset and one we are thrilled to have on our team.”
“I could not be more excited to join the MINDCURE team today,” said Tarik Lebbadi, COO, MINDCURE. “The company has an impressive vision and strategy in place, and I look forward to providing the commercial direction alongside Mrs. Ramsden. I have operated companies through all growth stages, from start-ups in technology to healthcare, and most recently in the cannabis industry through legalization. I believe that leading MINDCURE successfully will require lessons learned from all three, with our focus on proprietary technology, the importance of trust and science within healthcare, and establishing a culture of efficiency, focus, and compliance through growth and legalization. Perhaps most importantly, I am a passionate advocate of psychedelic medicines and believe in their potential to transform mental health care.”
About Tarik Lebbadi:
An accomplished executive within the healthcare and technology sectors, Mr. Lebbadi has over 13 years of international operational experience. He started his career as a software engineer but then moved to the business world to lead the medical division of Johnson & Johnson in Morocco. He later found a passion for scaling and structuring rapidly growing companies, and his most recent experience was in a strategic operational capacity at Aurora Cannabis through the industry’s legalization.
He holds a BA in Mathematics and Computer Science from Ripon College and an MBA from IESE Business School in Barcelona, Spain.
About Mind Cure Health (MINDCURE) Inc.
MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.
MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.
On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Mr. Lebbadi driving MINDCURE’s commercial team forward; Mr. Lebbadi being the right leader for MINDCURE and his intended impact on MINDCURE; and Mr. Lebbadi helping to further the development and commercialization of iSTRYM.
Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; Mr. Lebbadi will help MINDCURE to achieve its goals as expected; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.
Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Mr. Lebbadi may not help MINDCURE to achieve its goals as expected; Mr. Lebbadi may not help the development and commercialization of iSTRYM; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.
The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.
The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Mind Cure Health Inc.